Zobrazeno 1 - 10
of 62
pro vyhledávání: '"Dimosthenis, Skarlos"'
Autor:
George Pentheroudakis, Nikos Maniadakis, Dimosthenis Skarlos, Georgia Kourlaba, Angelos Koutras, Helen Gogas, Dimitrios Pectasides, George Fountzilas, Meletios A. Dimopoulos
Publikováno v:
Supportive Care in Cancer. 23:2045-2051
The aim of this study was to compare the effectiveness of prophylactic single fixed dose of pegfilgrastim and daily administration of filgrastim on febrile neutropenia (FN), severe neutropenia, treatment delay, and dose reduction in patients with bre
Autor:
Béranger Lueza, Lesley Seymour, C. Le Pechoux, Minoru Takada, Allan Price, S. Spiro, M. Pijls-Johannesma, M. O'Brien, Anne-Sophie Veillard, N. Murray, Nevin Murray, M. Takada, Taro Shibata, James Lovato, H. Choy, David H. Johnson, W. Blackstock, Jeffrey Crawford, Cécile Le Péchoux, Donald H. Johnson, J.P. Pignon, D.V. Skarlos, Jean-Pierre Pignon, William Blackstock, Mary O’Brien, Anne Sophie Veillard, Dirk Karel Maria De Ruysscher, Hak Choy, Baktiar Hasan, X. Wang, Bernard Lebeau, Urania Dafni, E. Paris, Suzanne E. Dahlberg, B. Lebeau, Madelon Pijls-Johannesma, Sylvie Chevret, Xiaofei Wang, Dirk De Ruysscher, L. Seymour, R. Arriagada, Emmanuelle Paris, Dimosthenis Skarlos, Allan Hackshaw, P. Baas, A. Price, Stephen G. Spiro, Rodrigo Arriagada, Paul Baas
Publikováno v:
Annals of Oncology
Annals of Oncology, Elsevier, 2016, 27 (10), pp.1818-1828. ⟨10.1093/annonc/mdw263⟩
Annals of Oncology, 2016, 27 (10), pp.1818-1828. ⟨10.1093/annonc/mdw263⟩
Annals of Oncology, Elsevier, 2016, 27 (10), pp.1818-1828. ⟨10.1093/annonc/mdw263⟩
Annals of Oncology, 2016, 27 (10), pp.1818-1828. ⟨10.1093/annonc/mdw263⟩
International audience; BackgroundChemotherapy combined with radiotherapy is the standard treatment of “limited-stage” small-cell lung cancer. However, controversy persists over the optimal timing of thoracic radiotherapy and chemotherapy.Materia
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c89b1669f60e81e5d43f7f690e3ca5a4
https://europepmc.org/articles/PMC5035783/
https://europepmc.org/articles/PMC5035783/
Autor:
Kalliopi Petraki, Georgios Panayiotakopoulos, Christos Christodoulou, Konstantinos Mileounis, Maria Ioannidou, Dimosthenis Skarlos, Nikolaos Doulas
Publikováno v:
International Journal of Dermatology. 55:1143-1145
Autor:
George Papaxoinis, Kalliopi Petraki, Ioannis Kostopoulos, Haralabos P. Kalofonos, Dimitrios Bafaloukos, Helen Gogas, Dimitrios Pectasides, Mattheos Bobos, Evangelos Lianos, Kitty Pavlakis, George Fountzilas, Dimosthenis Skarlos
Publikováno v:
Clinical Breast Cancer. 10:230-237
Purpose This phase II study sought to evaluate the efficacy of the paclitaxel-carboplatin combination as neoadjuvant chemotherapy in patients with locally advanced breast cancer (LABC). Patients and Methods A total of 46 patients with LABC and inflam
Autor:
Epaminondas Samantas, Gerasimos Aravantinos, George Fountzilas, Ioannis Xanthakis, Dimosthenis Skarlos, George Pentheroudakis, Eleni Galani, Irene Grimani, Dimitrios Pectasides, Evangelos Lianos, Eleni Timotheadou
Publikováno v:
Oncology. 77:107-112
Objective: Recombinant human granulocyte-colony-stimulating factors such as filgrastim and pegfilgrastim have been employed as primary and secondary prophylaxis against neutropenia in cancer patients receiving chemotherapy. This study was conducted t
Autor:
Evangelos Lianos, Evangelia Razis, Ioannis Kostopoulos, Dimosthenis Skarlos, George Fountzilas, Helen Gogas, Haralabos P. Kalofonos, Evangelos Briasoulis, Christos Christodoulou, Mattheos Bobos
Publikováno v:
Oncology. 76:275-285
Objective: Combination of trastuzumab and anthracyclines in metastatic breast cancer (MBC) is precluded due to cardiotoxicity. Pegylated liposomal doxorubicin (PLD) is the least cardiotoxic among the anthracyclines. We performed a phase II study of t
Autor:
Dimitrios Bafaloukos, A. Onyenadum, Dimosthenis Skarlos, George P. Stathopoulos, Eleni Timotheadou, Paris Kosmidis, Alexandros Papanikolaou, Evangelos Briasoulis, Christos Papadimitriou, Haralabos P. Kalofonos, Irene Grimani, Aristotelis Bamias, Pavlos Papakostas, Epaminondas Samantas, Spyridon Rizos, Gerasimos Aravantinos, Dimitrios Pectasides, George Fountzilas, Meletios A. Dimopoulos, Theofanis Economopoulos
Publikováno v:
European Journal of Cancer. 44:2169-2177
Introduction: The combination of Carboplatin and Paclitaxel is considered the standard of care as initial chemotherapy for Advanced Ovarian Cancer (AOC). We compared this regimen with the combination of Cisplatin, Paclitaxel and Doxorubicin. Patients
Autor:
Stephen D. Rubin, Patrice Viens, Cristina Oliva, Debasish F. Roychowdhury, Arlene Chan, B. Newstat, John Crown, Bella Kaufman, S. Stein, Mario Campone, Dimosthenis Skarlos, Michael F. Press, Charles E. Geyer, Deborah Lindquist, C. Gilles Romieu, Paolo Paoletti, Agnieszka Jagiełło-Gruszfeld, Neville Davidson, Tadeusz Pienkowski, Veira Gorbounova, Michelle Casey, Stephen Chan, Johannes Isaac Raats, David Cameron
Publikováno v:
Breast Cancer Research and Treatment. 112:533-543
Purpose Lapatinib is a small molecule, dual tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor type 2 (HER2). Initial results of a phase III trial demonstrated that lapatinib plus capecitab
Autor:
David Cameron, Tadeusz Pienkowski, Dimosthenis Skarlos, Arlene Chan, Charles E. Geyer, Deborah Lindquist, C. Gilles Romieu, Mario Campone, Stephen D. Rubin, John Crown, Neville Davidson, Stephen Chan, Cristina Oliva, Bella Kaufman, Agnieszka Jagiełło-Gruszfeld, Mark S. Berger, S. Stein, John K. Forster
Publikováno v:
New England Journal of Medicine. 355:2733-2743
Lapatinib, a tyrosine kinase inhibitor of human epidermal growth factor receptor type 2 (HER2, also referred to as HER2/neu) and epidermal growth factor receptor (EGFR), is active in combination with capecitabine in women with HER2-positive metastati
Autor:
Eleni Timotheadou, Ioannis Efstratiou, Christos Christodoulou, Theofanis Economopoulos, George Fountzilas, Pavlos Papakostas, Dimitrios G. Pectasides, Dimosthenis Skarlos, Helen Gogas, Christos Papadimitriou
Publikováno v:
Medical Oncology. 23:479-488
Currently, randomized phase III trials have demonstrated that docetaxel is an effective strategy in the adjuvant treatment of breast cancer. However, previous attempts to incorporate docetaxel with an anthracycline in a dose-dense regimen have been u